Concepedia

Author

Roger Echols

Shionogi (Japan)

Also Known As

Daniel Haverstock, Echols, Roger, R Echols, R M Echols, R. Echols, R. M. Echols, R.M. Echols, ROGER ECHOLS, ROGER M. ECHOLS, Roger Echols

178

Publications

7K

Citations

44

H-Index

83

Concepts

All Affiliations

Shionogi (Japan)Infectious Disease ConsultantsShionogi (United States)Albany Medical Center HospitalFutaba (Japan)
RE

About

Roger Echols is an author at Shionogi (Japan) specializing in medicine, antibiotics, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

32

2.9K

2

Health Sciences

10

12

1.3K

3

Allergy

1

1

61

4

Biomolecular Engineering

1

1

118

5

Cell Biology

1

1

40

Roger Echols

×

75

Publications

5.8K

Citations

38

H-Index

YearCitations

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga,

The Lancet Infectious Diseases

2020

732

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu,

The Lancet Infectious Diseases

2020

432

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols,

The Lancet Infectious Diseases

2018

387

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy

Deepak Kapoor, Ira Klimberg, G.H. Malek,

Urology

1998

251

<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

Meredith Hackel, Masakatsu Tsuji, Yoshinori Yamano,

Antimicrobial Agents and Chemotherapy

2017

225

<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)

Meredith Hackel, Masakatsu Tsuji, Yoshinori Yamano,

Antimicrobial Agents and Chemotherapy

2017

194

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

Bin Cai, Roger Echols, Glenn Magee,

Open Forum Infectious Diseases

2017

193

Results of a Randomized Trial Comparing Sequential Intravenous/Oral Treatment with Ciprofloxacin Plus Metronidazole to Imipenem/Cilastatin for Intra-Abdominal Infections

Joseph S. Solomkin, Harald H. Reinhart, E. Patchen Dellinger,

Annals of Surgery

1996

191

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

Krystyna M. Kazmierczak, Masakatsu Tsuji, Mark G. Wise,

International Journal of Antimicrobial Agents

2018

188

A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women

James McCarty, G. Richard, W Huck,

The American Journal of Medicine

1999

167

Page 1